ArticleMedical science monitor : international medical journal of experimental and clinical research2025
Evaluation of Inflammatory Biomarkers in Parotid Tumors.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluation of Systemic Inflammatory Markers in Predicting Malignancy in Parotid Gland Tumors.The Laryngoscope · 2026Observational
- Diagnostic value of the pan-immune-inflammation value, plateletcrit, and monocyte count in salivary gland tumors: a 10-year two-stage retrospective analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Salivary gland neoplasms present a diagnostic challenge due to their heterogeneous nature and varying histological subtypes. Recent studies have highlighted the potential role of inflammatory biomarkers, such as neutrophil to lymphocyte ratio (NLR) and systemic immune inflammation index (SII), in enhancing diagnostic accuracy for distinguishing between benign and malignant parotid gland tumors. This study aimed to evaluate the use of inflammatory biomarkers - NLR, platelet-to-lymphocyte ratio (PLR), SII, and systemic inflammation response index (SIRI) - in the differential diagnosis of parotid gland tumors. MATERIAL AND METHODS Patients who underwent parotidectomy in a single center between 2019 and 2023 were included. Inflammatory biomarkers (NLR, PLR, SII, SIRI) were calculated and compared according to histopathological features (benign vs malignant) and subgroups (benign: pleomorphic adenoma, Warthin, and others; and malignant: high grade, low grade, and lymphoma. RESULTS A total of 206 patients were included in the study (benign: 177, malignant: 29). No significant difference was detected in NLR, PLR, SII and SIRI values between benign and malignant tumor groups. While all inflammatory markers were found to be elevated, only PLR exhibited a statistically significant difference among high-grade, low-grade, and benign tumor groups (P=0.05). Patients with Warthin tumor revealed significantly lower PLR and higher SIRI values than those with pleomorphic adenoma (P=0.02 and P<0.001, respectively). CONCLUSIONS Evaluation of inflammatory biomarkers seems to play a promising role in diagnosing parotid tumors, especially Warthin tumor and high-grade malignancies. Due to their accessibility and cost-effectiveness, further studies are warranted to determine their accuracy and optimal use in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.